Komori
Shin Nippon Biomedical Laboratories (2395) · RiskMitigated

Human Rights Risks in Business Activities and the Supply Chain

First written in FY2023. 4 of 6 entries say "Restated". Latest entry: FY2026.

6entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY2026-H12023: 320232024: 120242025: 120252026: 12026
Same theme, other companies
Human rights violation risks in business operations and supply chainsA theme 56 companies write about · 56 as a headwind · 0 as a tailwind

18 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 56 companies compared. The sentences above are computed from all 56.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「事業活動およびサプライチェーンにおける人権への影響を特定・評価し、防止および軽減するため、人権デューデリジェンスを継続的に実施しています。」

    人権リスクへの対応として、事業活動およびサプライチェーンを対象とする人権デューデリジェンスの継続実施を開示した。
  2. FY2026-H1RestatedAnnual report

    「No new business or other risks arose during the current interim consolidated accounting period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    事業活動・サプライチェーンにおける人権リスクについて、重要な変更がないと記載している。
  3. FY2024-Q3RestatedAnnual report

    「No new business or other risks arose during the nine-month period ended December 31, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    事業活動・サプライチェーンにおける人権リスクについて、重要な変更がないと記載している。
  4. FY2024-Q2RestatedAnnual report

    「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    事業活動・サプライチェーンにおける人権リスクについて、重要な変更がないと記載している。
  5. FY2024-Q1RestatedAnnual report

    「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    事業活動・サプライチェーンにおける人権リスクについて、重要な変更がないと記載している。
  6. FY2023First statedAnnual report

    「①当社の事業活動により、サプライチェーンの取引先を含めて、直接または間接的に人権に影響を及ぼすリスク」

    役職員だけでなくサプライチェーン取引先を含む事業活動が人権に影響を及ぼし、社会要請に応えられない場合に企業価値が低下するリスクを初めて独立して示した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Shin Nippon Biomedical Laboratories's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.